Predictive information for staphylococci: oxacillin/methicillin-resistant isolates

For agents with established clinical efficacy and considering site of infection and appropriate dosing, methicillin (oxacillin)-susceptible staphylococci can be considered susceptible to:

• β-lactam combination agents (amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam)
• Oral cephems (cefaclor, cefdinir, cephalexin, cefpodoxime, cefprozil, cefuroxime, loracarbef)
• Parenteral cephems including cephalosporins I, II, III, and IV (cefamandole, cefazolin, cefepime, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefotetan, ceftizoxime, ceftriaxone, cefuroxime, ceftaroline, moxalactam)
• Carbapenems (doripenem, ertapenem, imipenem, meropenem)

Methicillin (oxacillin)-resistant staphylococci are resistant to all currently available β-lactam antimicrobial agents, with the exception of ceftaroline.

Reference:

CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 35^rd ed. CLSI guideline M100. Clinical and Laboratory Standards Institute; 2025.

For additional information, please contact the Clinical Microbiology Laboratory at 984-974-1805